Edap Technomed Prostatron is first microwave system approved by FDA for BPH.
This article was originally published in The Gray Sheet
Executive SummaryEDAP TECHNOMED PROSTATRON POSTMARKET STUDY NEARING COMPLETION, according to the Cambridge, Massachusetts firm. Edap says it is in the final stages of collecting follow-up data on 100 patients treated with the microwave-based system for benign prostatic hyperplasia (BPH). FDA conditioned its May 3 approval of the device's premarket approval application on collection of the postmarket data.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.